{"id":"gp100","name":"gp100 (PMEL)","symbol":"PMEL","route":"/targets/gp100/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10880","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185664","uniprot":"https://www.uniprot.org/uniprotkb/P40967/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P40967","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3712988","open-targets":"https://platform.opentargets.org/target/ENSG00000185664","civic":"https://civicdb.org/genes/6490/summary","oncokb":"https://www.oncokb.org/gene/PMEL","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PMEL","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=PMEL","depmap":"https://depmap.org/portal/gene/PMEL?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000185664-PMEL","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/6490","omim":"https://www.omim.org/entry/155550"}],"products":[{"id":"tebentafusp","name":"Tebentafusp","status":"approved","modality":"ImmTAC (TCR×CD3 bispecific)","route":"/drugs/tebentafusp/"}],"trials":[{"id":"nct05549297","name":"Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)","nct":"NCT05549297","phase":"3","status":"recruiting"},{"id":"imcgp100-202","name":"IMCgp100-202","nct":"NCT03070392","phase":"2","status":"positive"},{"id":"nct04262466","name":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","nct":"NCT04262466","phase":"1/2","status":"active"}],"pathways":[],"companies":["immunocore"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}